By Mareia Frost (Abzena)2023-02-24T09:00:58
In this article, Mareia Frost, Scientific Leader at Abzena, explores how understanding the characteristics of protein‑based drugs, and applying the right techniques, means even the most complex biologics can be effectively separated from potentially-harmful impurities.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-09-17T08:00:00
Sponsored by Mastercontrol
2026-06-16T13:00:00 2026-06-16T14:00:00
Sponsored by USP
2026-05-13T14:00:00 2026-05-13T15:00:00
Sponsored by Thermo Fisher Scientific
2026-03-04T15:00:00 2026-03-04T16:00:00
Sponsored by METTLER TOLEDO
2025-10-08T07:00:00
Sponsored by Entegris
2025-06-26T08:43:00
Sponsored by Uniphar, By Tom Smith (Uniphar)
Site powered by Webvision Cloud